Temple University Hospital

Main Line Health Names New Chief Nursing Officer

Retrieved on: 
Thursday, July 7, 2022
Magnet, Efficiency, Department, University of Pennsylvania Health System, Health, View, University, Temple University Hospital, Villanova University, Pleasure, Main Line Health, Senior, Imperial College COVID-19 Response Team, Workforce, COVID-19, Nurse practitioner, Internal medicine, National Association Medical Staff Services, Betty, Health Care for Women International, Lankenau Medical Center, Nursing, Pennsylvania Hospital, Technology, Communication, RN, DNP, Thomas Jefferson University, Bachelor of Science in Nursing, FAAN, Time, Leadership, Medical laboratory, Safety, Physician, Ecosystem, MD, Multimedia, Temple, Management, Medicine, Science, Woman

RADNOR, Pa., July 7, 2022 /PRNewswire/ -- Main Line Health today announces that Elizabeth (Betty) Craig, DNP, RN, FACHE, has been named Senior Vice President and Chief Nursing Officer for the System.

Key Points: 
  • RADNOR, Pa., July 7, 2022 /PRNewswire/ -- Main Line Health today announces that Elizabeth (Betty) Craig, DNP, RN, FACHE, has been named Senior Vice President and Chief Nursing Officer for the System.
  • Most recently, Craig served as the Chief Nursing Officer at Pennsylvania Hospital, part of the University of Pennsylvania Health System.
  • "It is a pleasure and privilege to have Betty Craig join Main Line Health's executive team and lead our outstanding nursing staff into the future," said Barbara Wadsworth, DNP, RN, FAAN, Chief Operating Officer, Main Line Health, and former Chief Nursing Officer for the System.
  • "We are thrilled Betty will be joining Main Line Health and partnering with our medical staff to achieve optimum results throughout the system," said Jonathan B. Stallkamp, MD, Chief Medical Officer, Main Line Health.

New Study Shows Virtual Bronchoscopic Navigation With Fused Fluoroscopy and Vessel Mapping Using Broncus Archimedes System is Safe and Effective in Obtaining High Biopsy Yield in Lung Tumors

Retrieved on: 
Friday, March 25, 2022
Biotechnology, Health, Surgery, Oncology, Risk, Blood, Marketing, Therapy, Cell, Lung, Temple University Hospital, Diagnosis, First Affiliated Hospital of Xinjiang Medical University, Biopsy, Archimedes, University of Pennsylvania, Shanghai Chest Hospital, Pulmonology, Planner, Respiratory disease, Pneumothorax, VBN, TBNA, Â, MD, Houston Methodist Hospital, Temple University, Fluoroscopy, Trial of the century, Beth Israel Deaconess Medical Center, Chair, Degenerative disease, Guangzhou Medical University, Lung cancer, University, Patient, Medical device, Medical imaging, Medicine

The prospective, single-arm, multicenter study of 104 patients studied biopsy yield (biopsy forceps and/or needle), sampling yield (including cytologic sampling) and diagnostic yield using the Archimedes System to guide bronchoscopic transparenchymal nodule access (BTPNA) and guided transbronchial needle aspiration (TBNA).

Key Points: 
  • The prospective, single-arm, multicenter study of 104 patients studied biopsy yield (biopsy forceps and/or needle), sampling yield (including cytologic sampling) and diagnostic yield using the Archimedes System to guide bronchoscopic transparenchymal nodule access (BTPNA) and guided transbronchial needle aspiration (TBNA).
  • The Archimedes VBN System combines fused fluoroscopy, real-time bronchoscopy and virtual bronchoscopic navigation for 3D views and access to nodules anywhere in the lung, with the ability to avoid major blood vessels through vessel mapping.
  • In this study, BTPNA showed a superior biopsy yield when compared to todays bronchoscopic diagnostic approaches.
  • Its lung cancer diagnostic and therapeutic portfolio includes the Archimedes System, Archimedes Lite Virtual Bronchoscopic Navigation (VBN) System, Archimedes Planner and FleXNeedle.

Temple University Hospital Adopts Masimo Centroid™

Retrieved on: 
Monday, February 7, 2022
Software, Nursing, Health, Medical Devices, Hospitals, Technology, University, Education, Connectivity, Carboxyhemoglobin, Sale, Radius, Temple Health, Gateway, RN, Health care, Mouth ulcer, Retinopathy, Premature, Motion, Iloilo, Vizient, Inc., Pressure, MASI, Solution, Bed, FDA, ICU, Temple University Hospital, DNP, Ulcer, National, U.S. News & World Report, NASDAQ, News, HACS, Incidence, Risk, Technology, Patient, Safety net, RD, Rx, Health, PVI, Multimedia, Ori, Automation, Respiration, Methemoglobin, Orientation, Hospital, Trauma, University, Hapi (Nile god), CEO, Movement, HAC, Oxygen saturation (medicine), Medical imaging, Health insurance, Centroid, Masimo, Temple University Hospital, MASIMO, TEMPLE UNIVERSITY HOSPITAL

Masimo (NASDAQ: MASI) and Temple Health today announced that Temple University Hospital (TUH) , a 722-bed academic medical center located in Philadelphia, is expanding its use of Masimo technologies with Centroid, an advanced wireless patient position, orientation, activity, and respiration rate sensor, at 100 beds across its ICU units.

Key Points: 
  • Masimo (NASDAQ: MASI) and Temple Health today announced that Temple University Hospital (TUH) , a 722-bed academic medical center located in Philadelphia, is expanding its use of Masimo technologies with Centroid, an advanced wireless patient position, orientation, activity, and respiration rate sensor, at 100 beds across its ICU units.
  • In addition, Centroid data can be relayed via the Masimo Hospital Automation platform to Patient SafetyNet, Masimos centralized remote patient supplemental monitoring platform, and Replica, a mobile application that allows clinicians to view continuous data regardless of location.
  • With the addition of Centroid, Temple adds another key Masimo innovation to their toolkit.
  • Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris Gateway, iSirona, Patient SafetyNet, Replica, Halo ION, UniView, UniView :60, and Masimo SafetyNet.

Dr. Cherag Daruwala of Hunterdon Gastroenterology Named 2021 NJ Top Doc

Retrieved on: 
Thursday, January 27, 2022
Hepatitis, Dentist, Cancer, Irritable bowel syndrome, Patient, List of Medknow Publications academic journals, Associate, Hunterdon Medical Center, Diagnosis, Temple University Hospital, Medical device, Central Jersey, Hepatology, Gastroenterology

SCOTCH PLAINS, N.J., Jan.27, 2022 /PRNewswire-PRWeb/ -- NJ Top Docs has reviewed and approved Dr. Cherag Daruwala of Hunterdon Gastroenterology Associates for 2021.

Key Points: 
  • SCOTCH PLAINS, N.J., Jan.27, 2022 /PRNewswire-PRWeb/ -- NJ Top Docs has reviewed and approved Dr. Cherag Daruwala of Hunterdon Gastroenterology Associates for 2021.
  • After completing his fellowship in Gastroenterology, Dr. Daruwala went on to complete training in endoscopic ultrasound and was on staff at Temple University Hospital for 3 years prior to joining Hunterdon Gastroenterology Associates in 2012.
  • Dr. Daruwala established the endoscopic ultrasound program at Hunterdon Medical Center.
  • NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel

Retrieved on: 
Tuesday, January 4, 2022
Ernest Mario School of Pharmacy, Arnold & Porter, Sidley Austin, University, Acceleron Pharma, Development, Acquisition, Temple University School of Medicine, General counsel, Patient, Degenerative disease, Disc, Medical director, Temple University Hospital, Pharming, University of Michigan Law School, Hematologic disease, Research and Development Council of New Jersey, Regulatory affairs, Hope, Marion Merrell Dow, Public health, Internal medicine, Compliance, Merck, Arnold, Hematology, Safety, Board, Hoechst AG, Samuel, Board of directors, Multimedia, Saint Louis University College for Public Health and Social Justice, Leadership, Rutgers University, Pharmaceutical industry, Medical device, Celgene, Medicine, Research, Pharmacy, Acceleron

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jay T. Backstrom, M.D., M.P.H., to its Board of Directors, and the appointment of Rahul Khara, Pharm.D., J.D., as General Counsel. Dr. Backstrom was most recently Executive Vice President, Head of Research and Development at Acceleron Pharma and Dr. Khara was most recently Vice President, Legal and Chief Compliance Officer, also at Acceleron Pharma.

Key Points: 
  • Dr. Backstrom joins the Disc Medicine Board with over 30 years of experience in research and development.
  • Dr. Khara joins Disc Medicine from Acceleron where he served as Vice President, Legal and Chief Compliance Officer.
  • Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.
  • Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.

Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Board of directors, Atlas Venture, Alta Partners, Safety, Board, Development, Growth, Atlas, Hoechst AG, Temple University Hospital, Science, Cancer, RA, Bluebird bio, Congenital disorders of amino acid metabolism, Medical director, Marion Merrell Dow, Sutro Biopharma, Center for Research and Development in Health Sciences, Patient, Internal medicine, Hematology, Saint Louis University College for Public Health and Social Justice, Drug development, Regulatory affairs, Temple University School of Medicine, Public health, Samuel, Pharmaceutical industry, Acceleron, Director, Research, Celgene

Jays exceptional clinical development acumen adds an important skill set to our Board of Directors as we develop our B cell medicine platform towards the clinic, said Joanne Smith-Farrell, Ph.D., Chief Executive Officer at Be Bio.

Key Points: 
  • Jays exceptional clinical development acumen adds an important skill set to our Board of Directors as we develop our B cell medicine platform towards the clinic, said Joanne Smith-Farrell, Ph.D., Chief Executive Officer at Be Bio.
  • I look forward to joining Be Bios Board of Directors and supporting this pioneering B cell therapy company through the next phase of growth and development towards the clinic, said Jay Backstrom, M.D., M.P.H.
  • Dr. Backstrom joins the Be Bio team with over 30 years of experience in research and development.
  • Be Biopharma is a leader in developing B cells as medicines, treating disease with the human bodys native protein factories.

Shirley Codada, MD, FAAHPM, To Lead Expanded Palliative Care Initiatives at Haven

Retrieved on: 
Monday, December 13, 2021
MHA, Nursing, Nursing care plan, Grief, Assistant, Practitioner, Health, View, American Academy, University, Family, Biology, Barry University, Social, Patient, Palliative care, H. Lee Moffitt Cancer Center & Research Institute, Multimedia, RN, Central Florida, American Academy of Hospice and Palliative Medicine, Prognosis, Physician, Hospital, Hospice, Advance care planning, Quality of life, Medical director, Chemistry, National Association Medical Staff Services, Temple University Hospital, Internal medicine, Miami Dade College, Corona Regional Medical Center, Hospice and palliative medicine, Medicine, MD, Haven, Science

GAINESVILLE, Fla., Dec. 13, 2021 /PRNewswire/ --Shirley Codada, MD, FAAHPM, Chief Medical Officer of Haven, North Central Florida's legacy mission-driven provider of hospice and palliative care, will lead an expanded community-based palliative care initiative across Haven's 18-county service area, announced Haven President and Chief Operating Officer Pauline Taylor, RN, MHA.

Key Points: 
  • GAINESVILLE, Fla., Dec. 13, 2021 /PRNewswire/ --Shirley Codada, MD, FAAHPM, Chief Medical Officer of Haven, North Central Florida's legacy mission-driven provider of hospice and palliative care, will lead an expanded community-based palliative care initiative across Haven's 18-county service area, announced Haven President and Chief Operating Officer Pauline Taylor, RN, MHA.
  • Joining Haven in summer of 2021, Dr. Codada brings a substantial background in both hands-on patient care and medical education to her leadership role at Haven.
  • About Palliative Care: Palliative care is specialized medical care for people living with a serious illness.
  • In addition to providing comfort through the compassionate delivery of hospice services, Haven offers Advance Care Planning, Palliative Care Consultations and Transitions services with a patient-centric focus.

Oscar Health Announces Temple Health Is Now In-Network, Expanding Access To Health Insurance and Care in Pennsylvania

Retrieved on: 
Wednesday, December 8, 2021
Professional Services, Health, Technology, Insurance, Managed Care, Software, NYSE, Pennie, Pharmacy, Health, Temple Health, St. Mary Medical Center, Medicare, Technology, Trinity Health Mid-Atlantic, Prescription, Fox Chase Cancer Center, PCP, HSA, OSCR, Software, Health care, ST, University of Pennsylvania Health System, Temple, Temple University Hospital, Small group, Individual, Fox Chase, Urgent care center, Health insurance, Hospital

These offerings, coupled with Oscars consumer-centric, tech-driven approach to health insurance, will provide residents with access to innovative, high-quality healthcare.

Key Points: 
  • These offerings, coupled with Oscars consumer-centric, tech-driven approach to health insurance, will provide residents with access to innovative, high-quality healthcare.
  • Providing high-quality healthcare is a necessity, and Temple Health, like Oscar, is committed to providing care that meets the individual needs of members while keeping them healthy.
  • Oscar members have 24/7 access to Oscar Virtual Urgent Care providers at $0, and $3 Tier 1 prescriptions.
  • Oscar Health, Inc. (Oscar) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members.

Israel's ALYN Hospital and Philadelphia International Medicine Join Forces to Advance Pediatric Medicine Worldwide

Retrieved on: 
Monday, November 8, 2021
Magee Rehabilitation Hospital, Health, Fox Chase Cancer Center, Disability, Main Line Health, Nemours Children's Hospital, Medicine, Education, Organization, Hospital, Knowledge, CEO, Research, ALYN Hospital, Rehabilitation, Partnership, Wills Eye Hospital, Birth, Physician, Nemours, Thomas Jefferson University Hospital, Temple University Hospital, Patient, PIM, Surgeon

ALYN Hospital, Pediatric & Adolescent Rehabilitation Center, Israel's renowned pediatric rehabilitation center, and Philadelphia International Medicine (PIM), a provider of specialized services and education that connects ten leading Philadelphia-area medical centers with the international community, are partnering to establish the ALYN-PIM Health Gateway Initiative.

Key Points: 
  • ALYN Hospital, Pediatric & Adolescent Rehabilitation Center, Israel's renowned pediatric rehabilitation center, and Philadelphia International Medicine (PIM), a provider of specialized services and education that connects ten leading Philadelphia-area medical centers with the international community, are partnering to establish the ALYN-PIM Health Gateway Initiative.
  • Within PIM's network, the partnership will initially focus on Nemours Children's Hospital, one of the largest and most respected pediatric medical institutions in the United States.
  • "Medical education, research, and innovation are ongoing activities at ALYN, and enhancing knowledge is always to our patients' benefit," said Dr. Maurit Beeri, Director General of ALYN Hospital.
  • https://www.philadelphiamedicine.com/
    Whitney Bain, ALYN Hospital and Philadelphia International Medicine, 954-379-2115, [email protected]

Tal Zaks Joins Strategic Advisory Board at Deep Genomics

Retrieved on: 
Tuesday, October 26, 2021
Health, Technology, Other Technology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, RNA transfection, MD, Research, University, Genomics, LinkedIn, Gene, Industry, Tesla, SpaceX, Oncology, Â, Deep learning, Twitter, Patient, Teva Pharmaceuticals, Ben-Gurion University of the Negev, Machine learning, Jazz Pharmaceuticals, RNA, Tuskegee Veterans Administration Medical Center, Leadership, FRSC, Life, Central Waqf Council, MA, CEO, Board, Internal medicine, COVID-19, Multimedia, Program, Lists of diseases, Artificial intelligence, Temple University Hospital, Therapy, Oligonucleotide, Doctor of Philosophy, GlaxoSmithKline, Clinical Genitourinary Cancer, Associate, Genetics, AI, Medical device, Pharmaceutical industry, Tal Zaks, MD, PhD, Deep Genomics, TAL ZAKS, MD, PHD, DEEP GENOMICS

Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, MD, PhD, to its Strategic Advisory Board, effective today.

Key Points: 
  • Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, MD, PhD, to its Strategic Advisory Board, effective today.
  • By applying its innovative AI platform to create oligonucleotides as programmable medicines, Deep Genomics has demonstrated remarkable productivity in advancing a broad pipeline of preclinical programs, says Zaks.
  • The strategic advisory board of Deep Genomics includes Jennifer Cook of BridgeBio, Denali Therapeutics and Jazz Pharmaceuticals, and Steve Jurvetson of SpaceX and Tesla.
  • Tal Zaks is Strategic Advisor at Deep Genomics, with a focus on growing the company to take advantage of the many targets, mechanisms and molecules generated by their programmable medicines platform.